Cell-free DNA (dd-cfDNA) transplant assessment test: What is the IP situation behind Natera’s Prospera™ test?

SOPHIA ANTIPOLIS, France – July 07, 2021 | Natera was founded by Matthew Rabinowitz, Ph.D., and Jonathan Sheena, M. Eng, in 2004. This American company provides DNA testing across multiple clinical areas including women’s health, organ health, and oncology. This DNA testing, involving a noninvasive blood-based test, is carried out using its next-generation cfDNA technology[…]

Beyond BioNTech and Moderna, will CureVac be the future leader in mRNA vaccines?

SOPHIA-ANTIPOLIS, France – February 01, 2021 | After three decades of research, mRNA-based vaccines have proven their safety and efficacy. They have finally reached the market, holding the promise to revolutionize the field. In December 2020, the FDA and EMA granted historic authorization to the first mRNA vaccine in the United States and in Europe.[…]

Biofidelity, the UK start-up about to revolutionise amplification-based cancer diagnostics

SOPHIA-ANTIPOLIS, France – August 31, 2020 | Biofidelity recently announced that it has raised $12 million, completing its Series A financing. The company disclosed that the series A investors are BlueYard Capital, Longwall Ventures and Agilent Technologies. Biofidelity is, above all, focused on developing non-small cell lung cancer detection assays that surpass the performance of[…]

Microneedle patch in the race for COVID-19 vaccine

SOPHIA-ANTIPOLIS, France – August 24, 2020 | The race to find a COVID-19 vaccine has highlighted several microneedle technologies for their advantages over common parenteral injections. Microneedles have shown immense potential, since they can efficiently, painlessly and safely deliver a vaccine through the skin. Microneedles reach the underlying dermis and epidermis, rich in antigen presenting[…]